» Articles » PMID: 19300456

Complex II Inhibition by 3-NP Causes Mitochondrial Fragmentation and Neuronal Cell Death Via an NMDA- and ROS-dependent Pathway

Overview
Specialty Cell Biology
Date 2009 Mar 21
PMID 19300456
Citations 120
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondrial respiratory complex II inhibition plays a central role in Huntington's disease (HD). Remarkably, 3-NP, a complex II inhibitor, recapitulates HD-like symptoms. Furthermore, decreases in mitochondrial fusion or increases in mitochondrial fission have been implicated in neurodegenerative diseases. However, the relationship between mitochondrial energy defects and mitochondrial dynamics has never been explored in detail. In addition, the mechanism of neuronal cell death by complex II inhibition remains unclear. Here, we tested the temporal and spatial relationship between energy decline, impairment of mitochondrial dynamics, and neuronal cell death in response to 3-NP using quantitative fluorescence time-lapse microscopy and cortical neurons. 3-NP caused an immediate drop in ATP. This event corresponded with a mild rise in reactive oxygen species (ROS), but mitochondrial morphology remained unaltered. Unexpectedly, several hours after this initial phase, a second dramatic rise in ROS occurred, associated with profound mitochondrial fission characterized by the conversion of filamentous to punctate mitochondria and neuronal cell death. Glutamate receptor antagonist AP5 abolishes the second peak in ROS, mitochondrial fission, and cell death. Thus, secondary excitotoxicity, mediated by glutamate receptor activation of the NMDA subtype, and consequent oxidative and nitrosative stress cause mitochondrial fission, rather than energy deficits per se. These results improve our understanding of the cellular mechanisms underlying HD pathogenesis.

Citing Articles

Neuroglobin-enriched secretome provides neuroprotection against hydrogen peroxide and mitochondrial toxin-induced cellular stress.

Bastari G, Solar Fernandez V, Muzzi M, Moreno S, Marino M, Fiocchetti M Cell Stress. 2024; 8:99-111.

PMID: 39600400 PMC: 11589466. DOI: 10.15698/cst2024.11.300.


Mitochondrial F0F1-ATP synthase governs the induction of mitochondrial fission.

Lhuissier C, Desquiret-Dumas V, Girona A, Alban J, Faure J, Cassereau J iScience. 2024; 27(5):109808.

PMID: 38741710 PMC: 11089353. DOI: 10.1016/j.isci.2024.109808.


Heat-Stress Impacts on Developing Bovine Oocytes: Unraveling Epigenetic Changes, Oxidative Stress, and Developmental Resilience.

Feng X, Li C, Zhang H, Zhang P, Shahzad M, Du W Int J Mol Sci. 2024; 25(9).

PMID: 38732033 PMC: 11084174. DOI: 10.3390/ijms25094808.


Drp1 controls complex II assembly and skeletal muscle metabolism by Sdhaf2 action on mitochondria.

Zhou Z, Ma A, Moore T, Wolf D, Yang N, Tran P Sci Adv. 2024; 10(14):eadl0389.

PMID: 38569044 PMC: 10990287. DOI: 10.1126/sciadv.adl0389.


Azilsartan Attenuates 3-Nitropropinoic Acid-Induced Neurotoxicity in Rats: The Role of IĸB/NF-ĸB and KEAP1/Nrf2 Signaling Pathways.

Hamouda H, Sayed R, Eid N, El-Sayeh B Neurochem Res. 2024; 49(4):1017-1033.

PMID: 38184805 PMC: 10901959. DOI: 10.1007/s11064-023-04083-8.


References
1.
Indo H, Davidson M, Yen H, Suenaga S, Tomita K, Nishii T . Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion. 2007; 7(1-2):106-18. DOI: 10.1016/j.mito.2006.11.026. View

2.
Bizat N, Galas M, Jacquard C, Boyer F, Hermel J, Schiffmann S . Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain. Neuropharmacology. 2005; 49(5):695-702. DOI: 10.1016/j.neuropharm.2005.04.030. View

3.
Mandavilli B, Boldogh I, Van Houten B . 3-nitropropionic acid-induced hydrogen peroxide, mitochondrial DNA damage, and cell death are attenuated by Bcl-2 overexpression in PC12 cells. Brain Res Mol Brain Res. 2005; 133(2):215-23. DOI: 10.1016/j.molbrainres.2004.10.033. View

4.
Behrens P, Franz P, Woodman B, Lindenberg K, Landwehrmeyer G . Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain. 2002; 125(Pt 8):1908-22. DOI: 10.1093/brain/awf180. View

5.
Brouillet E, Conde F, Beal M, Hantraye P . Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol. 1999; 59(5):427-68. DOI: 10.1016/s0301-0082(99)00005-2. View